Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb20717 · 1 trial · 28 indications
Treatment-related adverse events as assessed by CTCAE v4.03
| Arm | Type | Description |
|---|---|---|
| XmAb20717 | EXPERIMENTAL | XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles |
| Name | Type | Description |
|---|---|---|
| XmAb20717 | BIOLOGICAL | Monoclonal bispecific antibody |
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of one of the following advanced solid tumors: PART A (Dose Escalation Cohorts) 1. Melanoma; 2. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (triple-negative breast cancer; TNBC); 3. ...
Top 20 of 52 competitors
XmAb20717 is an investigational monoclonal antibody being studied in melanoma and other selected advanced solid tumors. It is not yet approved for any indication and remains in clinical development. Xencor, Inc. is evaluating it in adult patients with advanced cancers, including several tumor types beyond melanoma.
XmAb20717 targets PD-1 and CTLA-4, two immune checkpoint proteins. By binding both targets, it is designed to act on pathways that regulate T-cell activity in the tumor microenvironment. This dual-target approach distinguishes it from antibodies directed at only one of these checkpoints.
Xencor, Inc. (ticker XNCR) is developing XmAb20717. The company is the sponsor of the clinical program evaluating the antibody in advanced solid tumors, including melanoma. Xencor is a biopharmaceutical company focused on engineered antibody therapeutics.
XmAb20717 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 1 program has been completed, with a total of 150 participants enrolled across the studied advanced solid tumor types.
XmAb20717 has been evaluated in the Phase 1 trial NCT03517488, titled A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors. The trial enrolled 150 participants, was conducted in the United States, and is now completed. It studied melanoma along with multiple other advanced solid tumor types.
No. The Phase 1 trial of XmAb20717, NCT03517488, was an uncontrolled study without randomization or double-blinding. It enrolled 150 adults aged 18 years and older with selected advanced solid tumors, including melanoma, and used biomarker selection in its design.